[go: up one dir, main page]

EA201201234A1 - Составной белок - Google Patents

Составной белок

Info

Publication number
EA201201234A1
EA201201234A1 EA201201234A EA201201234A EA201201234A1 EA 201201234 A1 EA201201234 A1 EA 201201234A1 EA 201201234 A EA201201234 A EA 201201234A EA 201201234 A EA201201234 A EA 201201234A EA 201201234 A1 EA201201234 A1 EA 201201234A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nucleic acid
acid molecule
seq
polypeptide
sequence
Prior art date
Application number
EA201201234A
Other languages
English (en)
Other versions
EA023016B1 (ru
Inventor
Майнрад Гавац
Таня Шёнбергер
Хайдрун Деген
Гётц Мюнх
Ханс-Петер Хольтхофф
Андреас Бюльтманн
Ханс-Йёрг Бюринг
Кристоф Ледер
Original Assignee
Эдванскор Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эдванскор Гмбх filed Critical Эдванскор Гмбх
Publication of EA201201234A1 publication Critical patent/EA201201234A1/ru
Publication of EA023016B1 publication Critical patent/EA023016B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Выделенная молекула нуклеиновой кислоты выбрана из группы, к которой относятся: vi) молекула нуклеиновой кислоты, включающая нуклеотидную последовательность, которая как минимум на 85% идентична нуклеотидной последовательности SEQ ID NO: 1 или ее комплемента; vii) молекула нуклеиновой кислоты, включающая фрагмент как минимум из 1500 последовательных нуклеотидов нуклеотидной последовательности SEQ ID NO: 1 или ее комплемента; viii) молекула нуклеиновой кислоты, кодирующей полипептид, включающий аминокислотную последовательность, как минимум на 85% идентичную SEQ ID NO: 2; ix) молекула нуклеиновой кислоты, которая кодирует фрагмент полипептида, включающего аминокислотную последовательность SEQ ID NO: 2, причем фрагмент включает как минимум 500 заменимых аминокислот SEQ ID NO: 2; и х) молекула нуклеиновой кислоты, кодирующей полипептид, включающий гуманизированный иммуноглобулин или части иммуноглобулина, имеющие специфичность связывания с CD 133 молекула нуклеиновой кислоты, которая кодирует вариант полипептида, включающего аминокислотную последовательность SEQ ID NO: 2, причем молекула нуклеиновой кислоты гибридизируется с молекулой нуклеиновой кислоты, включающей полную последовательность SEQ ID NO: 1 или ее комплемент, в условиях инкубации при 45°С в 6,0×SSC с последующим промыванием в 0,2×SSC/0,l% SDS при 65°С.
EA201201234A 2010-04-07 2011-04-06 Составной белок EA023016B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10003744A EP2377888A1 (en) 2010-04-07 2010-04-07 Fusion protein
PCT/EP2011/001711 WO2011124370A1 (en) 2010-04-07 2011-04-06 Fusion protein

Publications (2)

Publication Number Publication Date
EA201201234A1 true EA201201234A1 (ru) 2013-04-30
EA023016B1 EA023016B1 (ru) 2016-04-29

Family

ID=42540350

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201234A EA023016B1 (ru) 2010-04-07 2011-04-06 Составной белок

Country Status (9)

Country Link
US (1) US20130130315A1 (ru)
EP (2) EP2377888A1 (ru)
JP (1) JP2013532954A (ru)
CN (1) CN102906116B (ru)
AU (1) AU2011238084B2 (ru)
CA (1) CA2795142A1 (ru)
EA (1) EA023016B1 (ru)
WO (1) WO2011124370A1 (ru)
ZA (1) ZA201207425B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160031991A1 (en) * 2013-03-15 2016-02-04 Vaccibody As Targeting vaccines for veterinary use
GB201411506D0 (en) * 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
CN105820246A (zh) 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型重组抗TNFα嵌合单克隆抗体制备方法及用途
CN113912697B (zh) * 2019-07-24 2023-05-30 暨南大学 靶向cd133的结合蛋白与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD110000A1 (ru) 1973-12-11 1974-12-05
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US20090130021A1 (en) * 2002-06-07 2009-05-21 Gotz Munch Methods, products and uses involving platelets and/or the vasculature
US20070071744A1 (en) * 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
EP1369128A1 (en) * 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
DE102007010306A1 (de) * 2007-02-22 2008-08-28 Eberhard-Karls-Universität Tübingen Universitätsklinikum Bispezifisches Fusionsprotein mit therapeutischem und diagnostischem Potenzial
KR101626988B1 (ko) * 2007-04-03 2016-06-02 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 이중특이적인 결합제들
EP2197911A2 (en) * 2007-09-14 2010-06-23 Amgen Inc. Homogeneous antibody populations
US8753630B2 (en) * 2008-02-12 2014-06-17 The Board Of Trustees Of The Leland Stanford Junior University Using EGFRvIII to identify and target cancer stem cells
DE102010013887A1 (de) * 2010-03-30 2011-10-06 Eberhard-Karls-Universität Tübingen Universitätsklinikum Fusionsprotein und dessen Verwendungen

Also Published As

Publication number Publication date
JP2013532954A (ja) 2013-08-22
EP2377888A1 (en) 2011-10-19
AU2011238084B2 (en) 2014-05-15
CN102906116B (zh) 2015-06-17
US20130130315A1 (en) 2013-05-23
CN102906116A (zh) 2013-01-30
CA2795142A1 (en) 2011-10-13
ZA201207425B (en) 2014-03-26
WO2011124370A1 (en) 2011-10-13
AU2011238084A1 (en) 2012-11-01
EA023016B1 (ru) 2016-04-29
EP2556092A1 (en) 2013-02-13

Similar Documents

Publication Publication Date Title
WO2011112089A3 (en) Mutated rep encoding sequences for use in aav production
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
EA200901430A1 (ru) Варианты фермента аспарагиназы и их применение
EA201001881A1 (ru) Пролинспецифичная протеаза из penicillium chrysogenum
NZ600348A (en) Anti-c5a binding moieties with high blocking activity
GB201206559D0 (en) Polypeptide
NZ596764A (en) N-glycan core beta-galactosyltransferase and uses thereof
NZ612323A (en) Nucleic acid molecules that confer resistance to coleopteran pests
MX2009009846A (es) Mejora del rendimiento tolerante al frio y a la sal de plantas con el gen de factor de transcripcion snac2 del arroz.
GB201201178D0 (en) Novel enzymes
NZ629051A (en) Glyphosate resistant plants and associated methods
RU2010116163A (ru) Вакцины и компоненты вакцин для подавления микробных клеток
MX2020005458A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
NZ598351A (en) Il-17 binding compounds and medical uses thereof
MX2012015139A (es) Polipéptido que tiene o que ayuda en la actividad de degradación del material de carbohidratos y usos del mismo.
NZ602351A (en) Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use
JP2012525819A5 (ru)
DK1824970T3 (da) Thricoderma reesei-glycoamylase og homologer heraf
EA201290559A1 (ru) Растения, устойчивые к гербицидам - ингибиторам hppd
MX392247B (es) Composiciones detergentes.
MX2012009847A (es) Celulasas de familia 5 modificada y usos de las mismas.
EA201300057A1 (ru) Полипептид, обладающий углеводдеградирующей активностью, и его применения
RU2011154363A (ru) Комбинации клад rrgb пневмококков
EA201201234A1 (ru) Составной белок
EP2589658A4 (en) PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU